Section
A phase 3 trial demonstrates that once-weekly oral islatravir-lenacapavir is as effective and safe as daily bictegravir-emtricitabine-tenofovir alafenamide in maintaining HIV-1 viral suppression, offering a promising option to improve adher
A Phase 3b trial in eastern and southern Africa showed that long-acting injectable cabotegravir plus rilpivirine is noninferior to oral dolutegravir-based therapy for maintaining viral suppression in HIV patients facing adherence challenges
The LATA trial demonstrates that long-acting injectable cabotegravir-rilpivirine given every 8 weeks is superior to daily oral ART for maintaining virological suppression in adolescents with HIV in sub-Saharan Africa, with a favorable safet
The REPRIEVE trial reveals higher heart failure incidence in people with HIV, particularly among women, Black participants in high-income regions, and those with hypertension or obesity. Traditional risk factors, not HIV-specific markers, w
A landmark pragmatic randomized controlled trial in Vietnam reveals that proactive Quitline referrals are as effective as nurse-led counseling and nicotine replacement therapy for smoking cessation among people living with HIV, offering a s
This randomized clinical trial explored if next-day HIV viral load results improve linkage to care. While overall linkage rates remained unchanged, the intervention significantly accelerated care initiation for individuals already living wi
A tailored approach to implementing systems navigation and psychosocial counselling significantly improved intervention fidelity and viral suppression among people with HIV who inject drugs in Viet Nam, compared to a standard strategy, high
A multinational prospective cohort found high viral suppression after switching or initiating tenofovir–lamivudine–dolutegravir (TLD), but emergent dolutegravir-resistance was detected in a small subgroup with prior virological failure and
In PASO‑DOBLE, switching virologically suppressed adults to dolutegravir/lamivudine maintained viral suppression at 48 weeks and was non‑inferior to switching to bictegravir/emtricitabine/tenofovir alafenamide, supporting shared decision‑ma
This review summarizes early-phase clinical trials assessing the safety, pharmacokinetics, and neutralisation activity of three innovative broadly neutralising monoclonal antibodies—N6LS, PGDM1400LS, and PGT121.414.LS—for HIV-1 prevention a
In a randomized phase 3b trial of pregnant women using the dapivirine vaginal ring or daily oral TDF/FTC for HIV prevention, 12‑month infant follow‑up showed no product‑related serious or grade 3+ adverse events and no HIV transmissions, su
A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuation
First randomized neonatal PK/safety data show 5 mg dolutegravir (dispersible tablet or oral film) every 48 hours for two weeks, then daily to day 28, achieves target troughs with acceptable safety in term infants born to mothers on dolutegr
In STRIDE‑7, the adult‑specific 21‑valent conjugate vaccine V116 produced robust opsonophagocytic responses across all 21 serotypes and had a favorable tolerability profile in adults living with HIV, supporting broader serotype coverage com
IMPAACT P1115 shows that initiating combination ART within 48 hours of birth can enable sustained ART‑free HIV‑1 remission for 48+ weeks in a subset of children with in‑utero infection, but careful selection, close monitoring and standardiz
A randomized phase 3b trial found no infant safety signals attributable to in-utero exposure to the dapivirine vaginal ring or oral tenofovir–emtricitabine PrEP over 12 months of follow-up, supporting use of both options for HIV prevention
Sleep disorders and depression are common in people living with HIV. Modafinil may improve daytime sleepiness, fatigue and cognition—especially for OSA-related EDS or augmentation in depression—but HIV-specific RCT data and ART interaction
Sleep disturbances and mood disorders profoundly affect people living with HIV. Modafinil emerges as a promising therapy addressing daytime sleepiness, depression, and cognitive challenges, improving quality of life.
NRTIs, traditionally used in HIV and HBV treatment, demonstrate promising anti-inflammatory effects that may reduce the incidence of age-related diseases by inhibiting inflammaging processes associated with endogenous retroelements.
Systematic review evidence supports accelerated epigenetic aging in people living with HIV compared to uninfected individuals, highlighting the need for further research considering antiretroviral therapy and confounding factors.
